Inhibition of the NF-κB pathway reduces inflammation in asthma models [37], [38], [39], [40], and several inhibitors of IKK2/IKKβ, an upstream kinase of NF-κB activation, have been successfully tested preclinically [41]. Here, IKBKB is linked to asthma.